Evidence map›Paper›PMID 27695045›Full record

ArticlePloS one2016

Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis.

Hossein Tezval, Natalia Dubrowinskaja, Inga Peters, Christel Reese, Katrin Serth, Faranaz Atschekzei, Jörg Hennenlotter, Arnulf Stenzl, Markus A Kuczyk, Jürgen Serth

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. DNA Methylation inCancers · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Role of DNA Methylation in Renal Cell Carcinoma.Molecular diagnosis & therapy · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hossein TezvalDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Natalia DubrowinskajaDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Inga PetersDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Christel ReeseDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Katrin SerthDepartment of Molecular Biology, Hannover Medical School, Hannover, Germany.
Faranaz AtschekzeiDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Jörg HennenlotterDepartment of Urology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Arnulf StenzlDepartment of Urology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Markus A KuczykDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Jürgen SerthDepartment of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relevance of Corticotropin Releasing Hormone (CRH)-system in human malignancies is a question of growing interest. Here we investigated hypermethylation and epigenetic silencing of the CRH-Binding Protein (CRHBP) gene in clear cell renal cell cancer (ccRCC). Relative methylation of the CRHBP CpG island (CGI) was determined in 17 tumor cell lines as well as 86 ccRCC samples and 66 paired normal tissues using pyrosequencing and quantitative methylation specific PCR of bisulfite converted DNA. Results were statistically compared with relative mRNA expression levels of CRHBP and clinicopathological parameters of patients. Re-expression of CRHBP following 5-aza-2´-deoxycytidine treatment was investigated by quantitative mRNA expression analysis. Real-time impedance analysis was applied for analysis of invasiveness of renal tumor cells following si-RNA knockdown of CRHBP expression or ectopic expression of CRHBP. We found the CRHBP CGI to be frequently methylated in tumor cell lines of renal, prostatic, and bladder cancer. Comparison of methylation in normal and paired renal cancer tissue specimens revealed hypermethylation of the CRHBP CGI in tumors (p<1*10-12). DNA methylation and decreased mRNA expression were correlated (R = 0.83, p<1*10-12). Tumor cell lines showed 5-aza-2´-deoxycytidine dependent reduction of methylation and re-expression of CRHBP was associated with altered cellular invasiveness of renal cancer cells in real-time impedance invasion assays. Hypermethylation and inverse relationship with mRNA expression were validated in silico using the TCGA network data. We describe for the first time tumor specific epigenetic silencing of CRHBP and statistical association with aggressive tumors thus suggesting the CRH system to contribute to the development of kidney cancer.

Indexed as

Gene SilencingAdultAgedAged, 80 and overCarcinoma, Renal CellCarrier ProteinsCell Line, TumorDNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisRNA, MessengerCarrier Proteinscorticotropin releasing factor-binding proteinRNA, Messenger

Identifiers

PMID27695045
PMCPMC5047469
OpenAlexW2528724099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.